Introduction:
Osteoarthritis (OA) is a leading cause of disability in the elderly. As estimated by the World Health Organization, it is one of the major causes of impaired function that reduces quality of life worldwide. The magnitude of this problem is likely to rise due to the increasing life expectancy and the increasing rates of obesity among the population. The goal of OA treatment is to control symptoms, prevent disease progression, minimize disability, and improve quality of life. The management can be divided into nonpharmacological interventions, pharmacological interventions, and surgical options. Pharmacological interventions can be further subdivided into symptomatic therapy and potential structure- or disease-modifying therapy. There are, at present, no specific pharmacological therapies that can prevent the progression of joint damage due to OA. Acetaminophen is the first line of therapy, although most of the patient requires NSAIDs. Risk of gastrointestinal (GI) bleeding and cardiovascular risk need to be considered, especially for elderly. With inflammatory components, intra-articular glucocorticoid injection gives short term benefit. Compared with corticosteroid injections, hyaluronic injections have similar clinical effects. But it is more costly. So far research with potential structure- and disease-modifying drugs in osteoarthritis includes tetracyclines, glycosaminoglycan polysulfuric acid, pentosan polysulfate, diacerein, glucosamine and others. Scientists are looking for new therapeutic targets like IL-1 receptor antagonist (IL-1Ra), mitogen-activated protein (MAP) kinases inhibitors, NF-kappaB inhibitors. Gene therapy, Chondrocyte and stem cell transplants showed some promise in animal models.

Pharmacotherapy for Osteoarthritis:
Pharmacologic interventions can be further subdivided into symptomatic therapy (Table-I) and potential structure- or disease-modifying therapy (Table-II).

Table-I
Symptom-Relieving Pharmacologic Therapies for Osteoarthritis

| Topical | Systemic | Intra-articular |
|---------|----------|----------------|
| Capsaicin | Acetaminophen | Corticosteroids |
| Topical nonsteroidal anti-inflammatory drug (NSAID) preparations | Nonselective NSAIDs | Hyaluronic acid derivatives |
| Tramadol | Cyclooxygenase-2 (COX-2)–specific inhibitors | |
| Narcotic analgesics | | |

1. MD (Rheumatology) – Final part student, BSMMU
2. Junior Consultant, Cardiology, BIRDEM
Correspondence: Dr. Rowsan Ara, FCPS (Medicine), MD (Rheumatology) – Final part student, BSMMU
Topical analgesics:
Topical NSAIDs and capsaicin may offer alternatives or adjunctive for patients with contraindications to use of systemic agents; or a suboptimal response to conventional therapy.

The long-term efficacy of topical NSAIDs is controversial. However, a meta-analysis of 4 trials lasting > 4 weeks found that diclofenac and etelac were effective for long-term pain relief in knee OA. However, a systematic review of topical NSAIDs in older patients with OA found that while topical application was associated with lower incidence of GI side effects, up to 15% of patients experienced a GI-related side effect. Further, up to 39.3% reported application site side effects.

Topical capsaicin works by depleting the neuropeptide substance P, and a meta-analysis of 3 trials confirmed that topical capsaicin is more effective than placebo for pain relief in OA. Capsaicin is commonly associated with a transient local burning sensation and must be used for 3 to 4 weeks to achieve maximal benefit. Despite these limitations, one study reported drop-out rates as low as 2%. Lidocaine 5% patches may also offer a topical alternative for pain relief in some patients with OA. In a randomized, open-label trial involving 143 adults with knee OA, pain relief achieved with lidocaine 5% patches was comparable with celecoxib 200 mg daily.

Acetaminophen and Nonsteroidal Anti-inflammatory Drugs:
Pharmacotherapeutic treatment options for mild-to-moderate pain associated with OA include acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs). While most data find NSAIDs to be more effective, acetaminophen is considered first-line therapy due to the side effect profile of NSAIDs.

A Cochrane review involving 5986 patients confirmed that acetaminophen was effective for reduction in overall OA pain and pain on motion. While this systematic review found that acetaminophen was more effective than placebo in 5 of 7 trials, the degree of overall pain relief was noted to be of questionable clinical significance. This review also found that NSAIDs were superior to acetaminophen in 12 trials. Another meta-analysis that evaluated the safety and efficacy of acetaminophen and NSAIDs found similar results with regard to the efficacy of these agents. Gastrointestinal (GI) side effects were more common in patients taking NSAIDs than in those taking acetaminophen (RR, 1.35; 95% confidence interval [CI]).

NSAIDs have consistently demonstrated efficacy for pain relief in OA, however, a meta-analysis of 23 trials that included 10 845 patients found that NSAIDs were only slightly more effective than placebo for short-term pain relief in OA of the knee. All NSAIDs, including cyclooxygenase-2 (COX-2)–selective agents, were equally effective for pain relief in OA.

Gastrointestinal and cardiovascular risks limit long-term use of NSAIDs in many older patients. Caution is recommended when NSAIDs are given to patients with cardiovascular risk factors. While COX-2–selective agents are most often associated with causing cardiovascular events, nonselective agents (eg, diclofenac and indomethacin) have also been implicated in increasing the risk of cardiovascular complications.

Narcotic analgesics:
The ACR recommends that opioid analgesics be limited to patients who have failed or cannot tolerate first-line treatment options for OA (eg, acetaminophen, NSAIDs, or tramadol) and continue to experience severe pain. The use of strong opioids for chronic, noncancer pain requires a full evaluation of the risks versus benefits for patients, especially older adults. A meta-analysis of 43 studies (28 of OA) was conducted to evaluate the safety, efficacy, and abuse potential of opioids for chronic, noncancer pain in older adults demonstrated that although opioids were effective in reducing pain, they also had the potential risk of reducing mental capacity in older adults.

Fentanyl transdermal patches provide continuous medication for 24 hours, but are not to be used in opioid-naive patients. According to Choquette et al 65% of patients experiencing moderate-to-severe pain due to knee or hip OA experienced an improvement in pain control.

Tramadol:
Tramadol may be considered an alternative option for patients who cannot tolerate NSAIDs for moderate-to-severe pain due to OA or as an adjunctive therapy with NSAIDs. An extended-release, once-a-day preparation of tramadol showed to relieve pain in OA of the knee and hip. Adverse effects are the primary reason for discontinuance of tramadol (up to 33%) when compared with placebo (6.3%). The lack of anti-inflammatory properties and tolerability to tramadol may limit its effectiveness in OA.

Intra-articular glucocorticoid injections:
Although there is no role for systemic corticosteroids in OA, local intra-articular corticoid preparations have a long history in the management of OA. Corticosteroid injections slow macrophage-like cell infiltration of the synovium in OA. These agents are useful for acute exacerbations of OA, but long-term pain relief has not been established.
Another trial attempted to assess the possible disease-modifying effects of corticosteroids by randomizing 68 patients to corticosteroid or saline injections of the knee every 3 months for 2 years. At the study’s end, there was no significant difference in rate of joint space narrowing.29

**Intra-articular hyaluronate injections:**
Hyaluronic acid helps to improve elasticity and viscosity in the joints. Compared with corticosteroid injections, hyaluronan injections have similar clinical effects (mean pain scores, 6.30 ± 1.0 standard deviation [SD] for hyaluronan treatment vs 6.40 ± 1.0 SD for corticosteroid treatment; (P = 0.42). However, they are more costly. One multicenter, randomized, double-blind study evaluated the issue of disease modification with hyaluronic acid but failed to demonstrate a disease-modifying effect for hyaluronan therapy.30

**Disease-Modifying Agents:**
Previously these agents were called chondroprotective. This was a misnomer, because the goal is to protect the entire joint (not only the cartilage). A workshop of the Osteoarthritis Research Society recommended that the term structure-modifying drugs be used for medications that previously would have been classified as chondroprotective.31 These drugs are intended to prevent, retard, stabilize, or even reverse the development of OA. Recently, the term disease-modifying osteoarthritis drug has been used for any such agent (Table-III)3 Unfortunately, to date, no drug has been conclusively proved to be structure or disease modifying in OA.

| Potential Structure- and Disease-Modifying Drugs in Osteoarthritis |
|---------------------------------------------------------------|
| Tetracyclines                                               |
| Metalloproteinase or collagenase inhibitors                 |
| Glucosamine                                                 |
| Diacerein                                                    |
| Growth factor and cytokine manipulation (interleukin-1 receptor antagonist [IL-1Ra], transforming growth factor-α) |
| Gene therapy (IL-1Ra, IL-1RII)                              |
| Chondrocyte and stem cell transplantation                   |

**Glycosaminoglycan polysulfuric acid (GAGPS):** It is a highly sulfated glycosaminoglycan, works by reducing the activity of collagenase, derived from bovine tracheal cartilage.37 In a canine model of OA, GAGPS was administered intra-articularly twice weekly for 4 weeks. Four weeks after completion of the GAGPS treatment, medial femoral condylar lesions had developed to a lesser degree in the treated group than in saline-treated dogs.38 In humans, OA of the knee was studied in a 5-year trial. There was improvement in multiple measured parameters, including less time lost from work.39

**Glycosaminoglycan-peptide complex (GP-C):** Also known as Rumalon, has been investigated. It has been shown to increase the levels of tissue inhibitor of metalloproteinases (TIMP)40. A randomized, placebo-controlled trial selected patients with hip or knee OA to receive 10 courses of injections of placebo or GP-C (2 mL) over 5 years (two courses per year). Each course consisted of 15 injections given twice weekly. GP-C failed to demonstrate a structure- or disease-modifying effect.41

**Pentosan polysulfate:** A hemicelluloses, in experimental studies of animal models suggested that it helps preserve cartilage proteoglycan content and retards cartilage degradation.42,43 However, a blinded, placebo-controlled study using an oral preparation in a dog model failed to demonstrate either a symptomatic benefit or a structure- or disease-modifying effect.44

**Diacerein:** Diacerein and its active metabolite rhein are anthraquinones related to senna compounds.45 They inhibit the synthesis of IL-1α in human OA synovium in vitro, as well as the expression of IL-1 receptors on chondrocytes.46 No effects have been reported on TNF or its receptors. Collagenase production and articular damage have been reduced in animal models.47,48,49

**Nutriceuticals:** Two nutritional supplements—glucosamine and chondroitin sulfate—have received significant attention for OA therapy (Table -III).3
Table-III

*Nutriceuticals for Osteoarthritis*

- Glucosamine
- Chondroitin sulfate
- Ginger extracts
- Avocado and soy unsaponifiables
- Cat’s claw
- Shark cartilage
- S-adenosyl methionine

**Glucosamine and Chondroitin sulfate:** Although in the 2005 meta-analysis of glucosamine there was a significant advantage of glucosamine over placebo for pain relief and functional improvement, further analyses indicating no significant difference in trials with adequate concealment (blinding) cast doubt on the efficacy of glucosamine sulfate.50 The combination of glucosamine and chondroitin sulfate, does not appear to be significantly more efficacious than placebo for pain relief or functional improvement in patients with OA of the knee. This was illustrated in the GAIT trial in which 1583 patients with painful OA of the knee were randomly assigned to one of three groups: placebo, glucosamine HCL (500 mg three time daily), chondroitin sulfate (400 mg three time daily), glucosamine plus chondroitin sulfate (500 mg + 400 mg three time daily), or celecoxib 200 mg/day.51

Other nutritional supplements, such as cat’s claw and shark cartilage, have become entrenched in regional and international popular cultures. Many people take them, despite limited or no data to support their use. A small, placebo-controlled trial showed improvement of OA pain with activity in those taking cat’s claw extracts.52 Shark cartilage contains a small amount of chondroitin sulfate.53 S-adenosyl methionine, a methyl group donor and oxygen radical scavenger, is often touted as a remedy for OA, although little evidence of its effectiveness has been published.54, 55

**Research with new therapeutic targets:**

**IL-1 receptor antagonist (IL-1Ra):** The potential methods of intervention in OA include growth factor and cytokine manipulation.56 Cytokines, such as IL-1 and TNF-α, are produced by the synovium and contribute to inflammation within osteoarthritic joints.57 Moreover, there may be deficient expression of naturally occurring anti-inflammatory compounds such as IL-1Ra by the chondrocytes of patients with OA.58 In some cases, increased nitric oxide production by OA articular chondrocytes may inhibit IL-1Ra synthesis.59 In a dog model of OA, IL-1Ra therapy reduced the expression of collagenase-1 in cartilage.60 The severity of cartilage lesions is also diminished.61 In a rabbit model of OA, transfer of the IL-1Ra gene to joints prevented OA progression62.

**The MAP kinase inhibitors:** The mitogen-activated protein (MAP) kinases are intracellular signaling proteins which play a central role in controlling the activity of pathways that regulate production and activity of multiple mediators of joint tissue destruction. The MAP kinase inhibition has the potential to slow disease progression in osteoarthritis and also might reduce pain; however, safety concerns have limited the use of general MAP kinase inhibitors in humans.63

**NF-kappaB inhibitors:** NF-kappaB transcription factors can be triggered by a host of stress-related stimuli including pro-inflammatory cytokines, excessive mechanical stress and ECM degradation products. Thus the NF-kappaB activating kinases are potential therapeutic OA targets. However, work remains in its infancy to evaluate the effects of efficacious, targeted NF-kappaB inhibitors in animal models of OA disease.64

**Gene therapy:** It has been attempted as well. The control of genes such as TIMP and MMPs would, in theory, provide the opportunity to modulate the patient’s disease. As previously noted, gene expression of IL-1Ra has already been tried in rabbits and dogs, as well as in an equine model of OA using an adenovirus vector.65

**Chondrocyte and stem cell transplants:** Chondrocyte and stem cell transplants into articular cartilage defects have been tried as well. Chondrocytes transplanted into human cartilage explants survived up to 45 days in vitro in one trial.66 Transfection of chondrocytes with the galactosidase gene has been successful both before and after transplantation.

**Conclusions:**

Still nonpharmacologic therapy is the cornerstone for OA management. Pharmacologic therapies are mainly aimed at symptomatic relief. The future holds promise for drugs that may genuinely modify structure, but these will require careful evaluation so that they may be appropriately positioned in the management of OA.

**Conflict Interest:** None

**References:**

1. Lopez AD, Murray JL, editors. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Cambridge, MA: Harvard School of Public Health on behalf of the World Health Organization and the World Bank; 1996
2. Lozada CJ, Altman RD: Osteoarthritis: A comprehensive approach to management. J Musculoskeletal Med 1997;14:26-38

3. Lozada CJ. Management of Osteoarthritis. In: Firestein GS, Budd RC, Harris ED Jr, McInnes IB, Ruddy S, Sergent JS, editors. Kelly’s Textbook of Rheumatology. 8th ed. Philadelphia: Saunders Elsevier; 2009. p.1563-73

4. Lin J, Zhang W, Jones A, Doherty M. Efficacy of topical non-steroidal anti-inflammatory drugs in the treatment of osteoarthritis: meta-analysis of randomised controlled trials. BMJ 2004;329:324

5. Biswal S, Medhi B, Pandhi P. Longterm efficacy of topical nonsteroidal antiinflammatory drugs in knee osteoarthritis: metaanalysis of randomized placebo controlled clinical trials. J Rheumatol. 2006;33(9):1841–4

6. Makris UE, Kohler MJ, Fraenkel L. Adverse effects of topical nonsteroidal antiinflammatory drugs in older adults with osteoarthritis: a systematic literature review. J Rheumatol 2010;37(6):1236–43

7. Zhang WY, Po LW. The effectiveness of topically applied capsaicin. A meta-analysis. Eur J Clin Pharmacol 1994;46(6):517–22

8. Deal CL, Schnitzer TJ, Lipstein E, Seibold JR, Stevens RM, Levy MD, et al. Treatment of arthritis with topical capsaicin: a double-blind trial. Clin Ther 1991;13(3):383–95

9. Gammaitoni AR, Galer BS, Onawola R, Jensen MP, Argoft CE. Lidocaine patch 5% and its positive impact on pain qualities in osteoarthritis: results of a pilot 2-week, open-label study using the Neuropathic Pain Scale. Curr Med Res Opin 2004;20(2):13–9

10. Kivitz A, Fairfax M, Sheldon EA, Xiang Q, Jones BA, Gammaitoni AR, et al. Comparison of the effectiveness and tolerability of lidocaine patch 5% versus celecoxib for osteoarthritis-related knee pain: post hoc analysis of a 12 week, prospective, randomized, active-controlled, open-label, parallel-group trial in adults. Clin Ther 2008;30(12):2366–77

11. Towheed TE, Maxwell L, Judd MG, Catton M, Hochberg MC, Wells G. Acetaminophen for osteoarthritis. Cochrane Database Syst Rev 2006;(1):CD004257

12. Zhang W, Jones A, Doherty M. Does paracetamol (acetaminophen) reduce the pain of osteoarthritis? A meta-analysis of randomised controlled trials. Ann Rheum Dis 2004;63(8):901–7

13. Towheed TE, Hochberg MC. A systematic review of randomized controlled trials of pharmacological therapy in osteoarthritis of the hip. J Rheumatol. 1997;24(2):349–57

14. Towheed TE, Hochberg MC. A systematic review of randomized controlled trials of pharmacological therapy in osteoarthritis of the knee, with an emphasis on trial methodology. Semin Arthritis Rheum 1997;26(5):755–70

15. Bjordal JM, Ljunggren AE, Kloving A, Slordal L. Nonsteroidal anti-inflammatory drugs, including cyclo-oxygenase-2 inhibitors, in osteoarthritic knee pain: meta-analysis of randomised placebo controlled trials. BMJ 2004;329(7478):1317

16. Watson MC, Brookes ST, Kirwan JR, Faulkner A. Non-aspirin, non-steroidal anti-inflammatory drugs for osteoarthritis of the knee. Cochrane Database Syst Rev 2000;(2):CD000142

17. McGgettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006;296(13):1633–44

18. American College of Rheumatology Subcommittee on Osteoarthritis. Recommendations for the medical management of osteoarthritis of the hip and knee. American College of Rheumatology Web site. http://www.rheumatology.org/practice/clinical/guidelines/oa-mgmt.asp. Published May 12, 2000. Accessed December 14, 2010

19. Papaleontiou M, Henderson CR Jr, Turner BJ, Moore AA, Olkhovskaya Y, Amano L, et al. Outcomes associated with opioid use in the treatment of chronic noncancer pain in older adults: a systematic review and meta-analysis. J Am Geriatr Soc 2010;58(7):1353–69

20. Solomon DH, Rassen JA, Glynn RJ, Garneau K, Levin R, Lee J, et al. The comparative safety of opioids for nonmalignant pain in older adults. Arch Intern Med 2010;170(22):1979–86

21. Choquette D, McCarthy TG, Rodrigues JF, Kelly AJ, Camacho F, Horbay GL, et al. Transdermal fentanyl improves pain control and functionality in patients with osteoarthritis: an open-label Canadian trial. Clin Rheumatol 2008;27(5):587–95

22. Kroenke K, Krebs EE, Bair MJ. Pharmacotherapy of chronic pain: a synthesis of recommendations from systematic reviews. Gen Hosp Psychiatry 2009;31(3):206–19

23. Gana TJ, Pascual ML, Fleming RR, Schein JR, Janagap CC, Xiang J, et al: Extended release tramadol in the treatment of osteoarthritis: A multicenter, randomized, double-blind, placebo-controlled clinical trial. Curr Med Res Opin 2006;22:1391-401

24. Rosenberg MT. The role of tramadol ER in the treatment of chronic pain. Int J Clin Pract 2009;63(10):1531–43

25. Cepeda MS, Camargo F, Zea C, Valencia L. Tramadol for osteoarthritis. Cochrane Database Syst Rev 2006; (3):CD005522

26. Young L, Katrib A, Cuello C, Vollmer-Conna U, Bertouch JV, Roberts-Thomson PJ, et al: Effects of intraarticular...
glucocorticoids on macrophage infiltration and mediators of joint damage in osteoarthritis synovial membranes: Findings in a double-blind, placebo-controlled study. Arthritis Rheum 2001;44:343-50

27. Bellamy N, Campbell J, Robinson V, Gee T, Bourne R, Wells G. Intraarticular corticosteroid for treatment of osteoarthritis of the knee. Cochrane Database Syst Rev 2006;(2):CD005328

28. Robinson P, Keenan AM, Conaghan PG. Clinical effectiveness and dose response of image-guided intra-articular corticosteroid injection for hip osteoarthritis. Rheumatology (Oxford) 2007;46(2):285–91

29. Raynauld JP, Buckland-Wright C, Ward R, Choquette D, Haraoui B, Martel-Pelletier J, et al: Safety and efficacy of long term intraarticular steroid injections in osteoarthritis of the knee: A randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2003;48:370-7

30. Jubb RW, Piva S, Beinat L, Dacre J, Gishen P. A one-year randomized, placebo (saline) controlled clinical trial of 500-730 kDa sodium hyaluronate (Hyalgan) on the radiological change in osteoarthritis of the knee. Int J Clin Pract 2003;57:467-74

31. Altman RD, Brandt K, Hochberg M, Moskowitz R, Bellamy N, Bloch DA, et al: Design and conduct of clinical trials in patients with osteoarthritis: Recommendations from a task force of the Osteoarthritis Research Society. Osteoarthritis Cartilage 1996;4:217-43

32. Amin AR, Attur MG, Thakker GD, Patel PD, Vyas PR, Patel RN, et al: A novel mechanism of action of tetracyclines: Effects on nitric oxide synthases. Proc Natl Acad Sci U S A 1996;93:14014-9

33. Tilley BC, Alarcón GS, Heyse SP, Trentham DE, Neuner R, Kaplan DA, et al: Minocycline in rheumatoid arthritis: A 48-week, double-blind, placebo-controlled trial. Ann Intern Med 1995;122:81-9

34. Cole AA, Chubinskaya S, Luchene LJ, Chlebek K, Orth MW, Greenwald RA, et al: Doxycycline disrupts chondrocyte differentiation and inhibits cartilage matrix degradation. Arthritis Rheum 1994;32:1727-34

35. Yu LP Jr, Smith GN Jr, Hasty KA, Brandt KD. Doxycycline inhibits type XI collagenolytic activity of extracts from human osteoarthritic cartilage and of gelatinase. J Rheumatol 1991;18:1450-2

36. Nüesch E, Rutjes AW, Trelle S, Reichenbach S, Jüni P. Doxycycline for osteoarthritis of the knee or hip. Cochrane Database Syst Rev 2009;(4):CD007323

37. Burkhardt D, Ghosh P. Laboratory evaluation of antiarthritic drugs as potential chondroprotective agents. Semin Arthritis Rheum 1987;17(1):3-34

38. Altman RD, Dean DD, Muniz OE, Howell DS. Prophylactic treatment of canine osteoarthritis with glycosaminoglycan polysulfuric acid ester. Arthritis Rheum 1989;32:759-66

39. Rejhołec V. Long-term studies of antiosteoarthritic drugs: An assessment. Semin Arthritis Rheum 1987;17(1):35-53

40. Howell DS, Altman RD. Cartilage repair and conservation in osteoarthritis. Rheum Dis Clin North Am 1993;19:713-24

41. Pavelká K, Gatterová J, Gollerova V, Urbanová Z, Sedláčková M, Altman RD, et al: A 5-year randomized controlled, double-blind study of glycosaminoglycan polysulfuric acid complex (Rumalon) as a structure modifying therapy in osteoarthritis of the hip and knee. Osteoarthritis Cartilage 2000;8:335-42

42. Golding JC, Ghosh P. Drugs for osteoarthrosis. I. The effects of pentosan polysulphate (SP54) on the degradation and loss of proteoglycans from articular cartilage in a model of osteoarthrosis induced in the rabbit knee joint by immobilization. Curr Ther Res 1983;32:173-84

43. Smith MM, Ghosh P, Numata Y, Bansal MK. The effects of orally administered calcium pentosan polysulfide on inflammation and cartilage degradation produced in rabbit joints by intra-articular injection of a hyaluronate-polylysine complex. Arthritis Rheum 1994;37:125-36

44. Innes JF, Barr AR, Sharif M. Efficacy of oral calcium pentosan polysulphate for the treatment of osteoarthritis of the canine stifle joint secondary to cranial cruciate ligament deficiency. Vet Rec 2000;146:433-7

45. Spencer CM, Wilde M. Diacerein. Drugs 1997;53:98-108

46. Martel-Pelletier J, Mineau F, Jolicoeur FC, Cloutier JM, Pelletier JP. In vitro effects of diacerein and rhein on interleukin 1 and tumor necrosis factor-alpha systems in human osteoarthritic synovium and chondrocytes. J Rheumatol 1998;25:753-62

47. Carney SL, Hicks CA, Tree B, Broadmore RJ. An in vivo investigation of the effect of anthraquinones on the turnover of aggrecans in spontaneous osteoarthritis in the guinea pig. Inflamm Res 1995;44:182-6

48. Brun PH. Effect of diacetylrhein on the development of experimental osteoarthritis: A biochemical investigation [letter]. Osteoarthritis Cartilage 1997; 5:289-91

49. Brandt KD, Smith G, Kang SY, Myers S, O’Connor B, Albrecht M. Effects of diacerein in an accelerated canine model of osteoarthritis. Osteoarthritis Cartilage 1997;5:438-49

50. Towheed TE, Maxwell L, Anastassiades TP, Shea B, Houpt J, Robinson V, et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev 2005:CD002946
51. Clegg DO, Reda DJ, Harris CL, Klein MA, O’Dell JR, Hooper MM, et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med 2006;354:795-808

52. Piscoya J, Rodriguez Z, Bustamante SA, Okuhama NN, Miller MJ, Sandoval M. Efficacy and safety of freeze-dried cat’s claw in osteoarthritis of the knee: Mechanisms of action of the species Uncaria guianensis. Inflamm Res 2001;50:442-8

53. Nadanaka S, Clement A, Masayama K, Faissner A, Sugahara K. Characteristic hexasaccharide sequences in octasaccharides derived from shark cartilage chondroitin sulfate D with a neurite outgrowth promoting activity. J Biol Chem 1998;273:3296-307

54. Barceló HA, Wiemeyer JC, Sagasta CL, Macías M, Barreira JC. Experimental osteoarthritis and its course when treated with S-adenosyl-L-methionine. Rev Clin Esp 1990;187:74-8

55. Montrone F, Fumagalli M, Sarzi Puttini P, Boccalessi L, Santandrea S, Volpato R, et al: Double-blind study of S-adenosyl-methionine versus placebo in hip and knee arthrosis. Clin Rheumatol 1985; 4: 484-5

56. Pelletier JP, Roughley PJ, DiBattista JA, McCollum R, Martel-Pelletier J. Are cytokines involved in osteoarthritic pathophysiology?. Semin Arthritis Rheum 1991; 20(2): 12-25

57. Smith MD, Triantafillou S, Parker A, Youssef PP, Coleman M. Synovial membrane inflammation and cytokine production in patients with early osteoarthritis. J Rheumatol 1997; 24: 365-71

58. Attur MG, Dave M, Cipolletta C, Kang P, Goldring MB, Patel IR, et al: Reversal of autocrine and paracrine effects of interleukin 1 (IL-1) in human arthritis by type II IL-1 decoy receptor: Potential for pharmacological intervention. J Biol Chem 2000; 275: 40307-5

59. Pelletier JP, Mineau F, Ranger P, Tardif G, Martel-Pelletier J. The increased synthesis of inducible nitric oxide inhibits IL-1ra synthesis by human articular chondrocytes: Possible role in osteoarthritic cartilage degradation. Osteoarthritis Cartilage 1996; 4: 77-84

60. Caron JP, Fernandes JC, Martel-Pelletier J, Tardif G, Mineau F, Geng C, et al: Chondroprotective effect of intraarticular injections of interleukin-1 receptor antagonist in experimental osteoarthritis: Suppression of collagenase-1 expression. Arthritis Rheum 1996; 39: 1535-44

61. Pelletier JP, Caron JP, Evans C, Robbins PD, Georgescu HI, Jovanovic D, et al: In vivo suppression of early experimental osteoarthritis by interleukin-1 receptor antagonist using gene therapy. Arthritis Rheum 1997; 40: 1012-9

62. Fernandes J, Tardif G, Martel-Pelletier J, Lascau-Coman V, Dupuis M, Moldovan F, et al. In vivo transfer of interleukin-1 receptor antagonist gene in osteoarthritic rabbit knee joints: Prevention of osteoarthritis progression. Am J Pathol 1999; 154: 1159-69

63. Richard F, Loeser, Elizabeth A. Erickson, and David L. Longa Mitogen-Activated Protein Kinases as Therapeutic Targets in Osteoarthritis Curr Opin Rheumatol 2008; 20(5): 581–6

64. Marcu KB, Otero M, Olivotto E, Borzi RM, Goldring MB. NF-kappaB signaling: multiple angles to target OA. Curr Drug Targets 2010; 11(5): 599-613

65. Frisbie DD, Ghivizzani SC, Robbins PD, Evans CH, McIlwraith CW. Treatment of experimental equine osteoarthritis by in vivo delivery of the equine interleukin-1 receptor antagonist gene. Gene Ther 2002; 9: 12-20

66. Doherty PJ, Zhang H, Tremblay L, Manolopoulos V, Marshall KW. Resurfacing of articular cartilage explants with genetically-modified human chondrocytes in vitro. Osteoarthritis Cartilage 1998; 6: 153-9